Kimberly-Clark nears $3.5 billion sale of global tissue business to Suzano, WSJ reports

Kimberly-Clark is reportedly nearing a $3.5 billion sale of its Kleenex and tissue businesses outside North America to Brazilian pulpmaker Suzano; a deal could be finalized as soon as Thursday. The unit, generating approximately $500 million in annual EBITDA, was put on the block as part of a restructuring initiated last year amid challenges from U.S. trade tariffs that have weighed on Kimberly-Clark's business outlook.

Analysis

Kimberly-Clark (KMB) is reportedly nearing the divestiture of its Kleenex and tissue businesses outside North America to Brazilian pulpmaker Suzano for approximately $3.5 billion, a transaction potentially concluding as early as this Thursday. This strategic move is a key component of a broader restructuring initiative KMB commenced last year, driven by significant headwinds from U.S. trade tariffs which contributed to a downward revision of its annual profit forecast in April due to escalating costs. The international unit targeted for sale generates approximately $500 million in annual EBITDA, implying a valuation multiple of around 7x based on the reported sale price. While this $3.5 billion figure is slightly below a previously cited $4 billion valuation during earlier bidding stages involving other parties like Royal Golden Eagle and Asia Pulp & Paper Co, the divestiture is aimed at enabling KMB to streamline its portfolio and potentially mitigate the financial impact of ongoing trade policy challenges. For Suzano, this acquisition represents a significant expansion of its tissue operations, building upon its 2022 purchase of KMB's Brazilian tissue assets. The per-ticker sentiment for KMB (-0.2) reflects the underlying operational pressures necessitating such restructuring, whereas Suzano's sentiment (0.5) suggests a cautiously positive market view on the acquisition, although Reuters has not yet confirmed the report.

Key Decisions for Investors

• Kimberly-Clark investors should assess if this $3.5 billion divestiture, at an approximate 7x EBITDA multiple, sufficiently de-risks the company from tariff-related pressures and facilitates a more focused strategy, while noting the sale price is potentially below earlier private market valuation discussions.
• For Suzano, this acquisition signals continued strategic expansion in the tissue sector; investors should evaluate the potential synergies, integration risks, and the financial impact of incorporating KMB's international assets at this valuation.
• Given the unconfirmed nature of the report, investors should await official announcements for clarity on the transaction's specifics and its precise strategic implications for both Kimberly-Clark and Suzano before making significant portfolio adjustments.